Health Care·Biotechnology·$20.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-2.11 | N/A | +18.75% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-2.11 | N/A | +18.75% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed cautious optimism about future developments. They are focused on navigating current challenges while continuing to invest in research and development.
Management highlighted ongoing efforts to innovate and adapt in a challenging market.
They emphasized the importance of maintaining a strong pipeline despite current financial pressures.
Moderna's earnings report shows a smaller-than-expected loss per share, which contributed to a positive stock reaction, rising 5.29%. The company did not provide revenue figures or future guidance, leaving some uncertainty. Investors may view the EPS beat as a sign of resilience, but the lack of revenue data could raise questions about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
TRIMBLE INC
Feb 10, 2026